CN101072573A - 用于预防或治疗动脉粥样硬化疾病的细菌组合物 - Google Patents

用于预防或治疗动脉粥样硬化疾病的细菌组合物 Download PDF

Info

Publication number
CN101072573A
CN101072573A CNA200580041763XA CN200580041763A CN101072573A CN 101072573 A CN101072573 A CN 101072573A CN A200580041763X A CNA200580041763X A CN A200580041763XA CN 200580041763 A CN200580041763 A CN 200580041763A CN 101072573 A CN101072573 A CN 101072573A
Authority
CN
China
Prior art keywords
lactobacillus
bacteria composition
composition comprises
individuality
application
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA200580041763XA
Other languages
English (en)
Chinese (zh)
Inventor
伊万·派特亚耶夫
安德烈亚·普法伊费尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cambridge Theranostics Ltd
Original Assignee
Cambridge Theranostics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cambridge Theranostics Ltd filed Critical Cambridge Theranostics Ltd
Publication of CN101072573A publication Critical patent/CN101072573A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CNA200580041763XA 2004-11-05 2005-11-01 用于预防或治疗动脉粥样硬化疾病的细菌组合物 Pending CN101072573A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0424552A GB0424552D0 (en) 2004-11-05 2004-11-05 Methods and means
GB0424552.8 2004-11-05

Publications (1)

Publication Number Publication Date
CN101072573A true CN101072573A (zh) 2007-11-14

Family

ID=33523284

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA200580041763XA Pending CN101072573A (zh) 2004-11-05 2005-11-01 用于预防或治疗动脉粥样硬化疾病的细菌组合物

Country Status (6)

Country Link
US (1) US20080166330A1 (https=)
EP (1) EP1812024A1 (https=)
JP (1) JP2008519018A (https=)
CN (1) CN101072573A (https=)
GB (1) GB0424552D0 (https=)
WO (1) WO2006048628A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107073046A (zh) * 2014-09-30 2017-08-18 深圳华大基因科技有限公司 拟杆菌属在预防和治疗冠状动脉疾病中的用途
CN107208037A (zh) * 2014-09-30 2017-09-26 深圳华大基因科技有限公司 拟杆菌属在预防和治疗冠状动脉疾病中的用途
CN121421987A (zh) * 2025-12-31 2026-01-30 中国医学科学院生物医学工程研究所 抗体靶向修饰双菌-益生元递送系统及制备方法和应用

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080254011A1 (en) * 2007-04-11 2008-10-16 Peter Rothschild Use of selected lactic acid bacteria for reducing atherosclerosis
EP2022502A1 (en) * 2007-08-10 2009-02-11 Nestec S.A. Lactobacillus rhamnosus and weight control
US20110189149A1 (en) * 2008-06-20 2011-08-04 Remy Burcelin New Uses of Lactic Acid Bacteria and Bifidobacteria
US8777025B1 (en) * 2011-08-18 2014-07-15 Whirlpool Corporation Modular hanging solutions for a household appliance
WO2018181071A1 (ja) * 2017-03-28 2018-10-04 森永乳業株式会社 非コラーゲン性糖タンパク質分解用組成物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5927833A (ja) * 1982-08-06 1984-02-14 Advance Res & Dev Co Ltd コレステロール乃至トリグリセリド低下剤
JPS61109729A (ja) * 1984-11-05 1986-05-28 Advance Res & Dev Co Ltd コレステロ−ル低下剤
DE69426186T2 (de) * 1993-05-11 2001-05-17 Otsuka Pharma Co Ltd Antioxidans-nahrungsmittel, antioxidans-herstellung und methode zur verringerung der oxidation
SE510753C2 (sv) * 1997-08-05 1999-06-21 Probi Ab Användning av en stam av Lactobacillus för tillverkning av ett läkemedel för reduktion av fibrinogenhalten i blod
DE69929321T2 (de) * 1998-04-01 2006-09-14 Ganeden Biotech, Inc., San Diego Erfahren zür verringerung von cholesterin mit bacillus coagulans sporen, systeme un zusammensetzungen
AUPR101600A0 (en) * 2000-10-25 2000-11-16 Atheromastat Pty Ltd Compositions and methods for diagnosis and treatment of cardiovascular disorders
GB2380481B (en) * 2001-08-22 2003-12-03 Cambridge Theranostics Ltd Means for treatment of atherosclerosis

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107073046A (zh) * 2014-09-30 2017-08-18 深圳华大基因科技有限公司 拟杆菌属在预防和治疗冠状动脉疾病中的用途
CN107208037A (zh) * 2014-09-30 2017-09-26 深圳华大基因科技有限公司 拟杆菌属在预防和治疗冠状动脉疾病中的用途
CN121421987A (zh) * 2025-12-31 2026-01-30 中国医学科学院生物医学工程研究所 抗体靶向修饰双菌-益生元递送系统及制备方法和应用

Also Published As

Publication number Publication date
US20080166330A1 (en) 2008-07-10
GB0424552D0 (en) 2004-12-08
WO2006048628A1 (en) 2006-05-11
JP2008519018A (ja) 2008-06-05
EP1812024A1 (en) 2007-08-01

Similar Documents

Publication Publication Date Title
US20250302733A1 (en) Dermatological preparations for maintaining and/or restoring healthy skin microbiota
Kondepudi et al. Prebiotic-non-digestible oligosaccharides preference of probiotic bifidobacteria and antimicrobial activity against Clostridium difficile
JP6182628B2 (ja) 免疫疾患の処置において使用するための、プロバイオティック細菌を含む組成物
Tuohy et al. Using probiotics and prebiotics to improve gut health
Costalos et al. Enteral feeding of premature infants with Saccharomyces boulardii
Trejo et al. Inhibition of Clostridium difficile growth and adhesion to enterocytes by Bifidobacterium supernatants
US20210177915A1 (en) Probiotics and methods of obtaining same
TWI342750B (https=)
Girardin et al. Indications for the use of probiotics in gastrointestinal diseases
DK2270133T3 (en) Method of obtaining a new strain of Bifidobacterium bidifum with effect against infection with Helicobacter pylori
TWI594758B (zh) 包含雙歧桿菌的組合物、其製備方法及其用途
EP2707010B1 (en) Bacterial strains belonging to the genus bifidobacterium for use in the treatment of hypercholesterolaemia
EP2627198B1 (en) Immunoadjuvant
CN103476273A (zh) 应用于胃肠疾病的两歧双歧杆菌菌株
US11213553B2 (en) Hypolipidemic effects of Bacillus coagulans
CA3245197A1 (en) NEW MICROBIAL COMPOSITION AND ITS METHODS OF USE
CN114040770B (zh) 用于治疗、缓和或预防痤疮的组合物
CN101072573A (zh) 用于预防或治疗动脉粥样硬化疾病的细菌组合物
Vijaya Kumar et al. Beneficial effects of probiotics and prebiotics on human health
US9272007B2 (en) Strain of L. bulgaricus capable of inhibiting the adhesion of H. pylori strains to epithelial cells
HK1110239A (en) Bacterial compositions for prevention or treatment of atherosclerotic disorders
US20240197762A1 (en) Nutritional composition for stimulationg bifidobacteria
Tarrah Characterization and Assessment of Health-related Probiotic Properties of Newly Isolated Lactic Acid Bacteria and Study of their Technological Potential by In-silico, In-vitro, and In-vivo Approaches
Prajapati et al. Role of probiotics in ulcerative colitis
Javid et al. Effects of Consumption of Probiotic Yogurt on Salivary Streptococcus mutans, IL-1β and TNF-α Levels in Adults with Initial Stages of Dental Caries: a Randomized, Double‑Blind, Placebo‑Controlled Clinical Trial

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1110239

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20071114

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1110239

Country of ref document: HK